Anthony Tennyson

Awakn Shares Its Q2 2022 Results, Showing Consistent Growth On Its Second Full Financial Year

Psychedelics Companies Seek Innovative Methods To Deliver Assisted Therapies, This One Stands Out

Awakn's Second Licensing Partnership Agreement In A Week, This Time In Canada: Ketamine For Pain Comorbidities

Psychedelics Companies Seek Innovative Methods To Deliver Assisted Therapies, This One Stands Out

Awakn's Second Licensing Partnership Agreement In A Week, This Time In Canada: Ketamine For Pain Comorbidities

Awakn Enters U.S. Addiction Treatment & Relapse Prevention Market With Ketamine Therapy For Alcohol Use Disorder

Phase 3 Trial On Ketamine Therapy Gets Almost $2M From UK State Funding

Awakn Enters U.S. Addiction Treatment & Relapse Prevention Market With Ketamine Therapy For Alcohol Use Disorder

Phase 3 Trial On Ketamine Therapy Gets Almost $2M From UK State Funding

UK To Fund Development Of Awakn's Ketamine-Assisted Therapy Program For Alcohol Use Disorder In US And UK

Ketamine Therapy Shows Potential In Treatment Of Alcohol Use Disorder, New Study Finds

Anthony Tennyson Recent News

UK Psychedelics Co. Awakn Life Sciences Begins Listing On OTC Markets

Awakn Life Sciences Corp. (NEO: AWKN) (OTC Pink: AWKNF), a biotech company with clinical operations in the psychedelics space looking at the UK mental health markets, began trading on Monday in the U.S. OTC markets under the symbol “AWKNF.”

Awakn Life Sciences: Tackling Britain's Addiction Problems With MDMA and Ketamine

Awakn Life Sciences Corp. (NEO: AWKN), a biotech company that develops psychedelics treatments for addiction, began trading on the NEO exchange last week.